Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2665497 | 0.76 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL8864287 | 0.76 | — | — | |
| SCHEMBL30687007 | 0.74 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL14691632 | 0.71 | — | — | |
| SCHEMBL789243 | 0.69 | — | — | |
| SCHEMBL22042637 | 0.68 | — | — | |
| SCHEMBL28355270 | 0.68 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL231670 | 0.67 | — | — | |
| SCHEMBL4885993 | 0.67 | — | — | |
| SCHEMBL951810 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518093-B2 | Topical formulation of arginine-rich cyclic antimicrobial peptides | NOVABIOTICS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| US-20160168203-A1 | Cyclic Antimicrobial Peptides | NOVABIOTICS LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| US-9181303-B2 | Treatment of bacterial infections with cyclic antimicrobial peptides | NOVABIOTICS LIMITED (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20140303071-A1 | CYCLIC ANTIMICROBIAL PEPTIDES | NOVABIOTICS LTD (GB) | 2014-10-09 | — | — | US | disclosed |
| US-8785375-B2 | Cyclic antimicrobial peptides for treating bacterial infections | NOVABIOTICS LTD. (GB) | 2014-07-22 | — | — | US | disclosed |
| CN-101389642-B | Cyclic antimicrobial peptides | NOVABIOTICS LTD | 2013-08-07 | — | — | CN | disclosed |
| US-20120316103-A1 | CYCLIC ANTIMICROBIAL PEPTIDES | NOVABIOTICS LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| EP-1976863-B1 | CYCLIC ANTIMICROBIAL PEPTIDES | NOVABIOTICS LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-8324154-B2 | Treatment of fungal infections with cyclic antimicrobial peptides | Novabiotics, Ltd. (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2357190-A2 | Cyclic antimicrobial peptides | Novabiotics Limited (GB) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357191-A2 | Cyclic antimicrobial peptides | Novabiotics Limited (GB) | 2011-08-17 | — | — | EP | disclosed |
| EP-2348039-A2 | Cyclic antimicrobial peptides | Novabiotics Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| CN-101389642-A | Cyclic antimicrobial peptides | NOVABIOTICS LTD (GB) | 2009-03-18 | — | — | CN | disclosed |
| WO-2007072037-A9 | CYCLIC ANTIMICROBIAL PEPTIDES | NOVABIOTICS LTD (GB) | 2009-03-05 | — | — | WO | disclosed |
| US-20090023641-A1 | Cyclic Antimicrobial Peptides | NOVABIOTICS LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1976863-A1 | CYCLIC ANTIMICROBIAL PEPTIDES | Novabiotics Limited (GB) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007072037-A1 | CYCLIC ANTIMICROBIAL PEPTIDES | NOVABIOTICS LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023641-A1 | Cyclic Antimicrobial Peptides | VIP, FPR3, FPR1 | HSD11B1 4305/4885 |
| US-20120316103-A1 | CYCLIC ANTIMICROBIAL PEPTIDES | VIP, FPR3, FPR1 | HSD11B1 4305/4885 |
| US-20140303071-A1 | CYCLIC ANTIMICROBIAL PEPTIDES | VIP, FPR3, FPR1 | HSD11B1 4305/4885 |
| US-20160168203-A1 | Cyclic Antimicrobial Peptides | VIP, FPR3, FPR1 | HSD11B1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.